Age-Related Macular Degeneration (ARMD) Clinical Trials

Find Age-Related Macular Degeneration (ARMD) Clinical Trials Near You

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

National Ophthalmic Genotyping and Phenotyping Network, Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

Background: The eyeGENE (Registered Trademark) program is a research resource for inherited eye conditions which includes genotypic and phenotypic data, imaging, and a corresponding biobank of DNA samples from people with a variety of eye diseases. Since 2007 this registry has been helping researchers learn more about the genetic sources for many inherited eye diseases. These findings helped them create better treatments. Now researchers want to expand eyeGENE (Registered Trademark) to include more people for certain eye diseases.

Objective: To collect information and DNA samples for the study of eye diseases. * Primary objective --To expand the current eyeGENE (Registered Trademark) data repository with targeted participant accrual * Secondary objectives * To enhance recruitment for clinical trials and investigations in inherited eye diseases * To establish genotype-phenotype correlations for rare eye diseases

Eligibility: People of any age with certain eye diseases. These can include aniridia; Best disease; blue-cone monochromacy; corneal dystrophy; and disorders of pigmentation, such as albinism. Relatives unaffected by the eye disease of interest may also be needed.

Design: Researchers will select participants based on their diagnosis. The data may include images and test results from eye exams. Participants will provide a sample of saliva. They will receive a kit with written instructions. They will spit in a tube and mail it to the NIH. Participants may be asked to provide a blood sample. The blood may be drawn at the NIH or at a local clinic. The eyeGENE (Registered Trademark) repository will offer researchers data about the participants eye conditions. The data may include pictures of their eyes, results of the genetic testing, and history of other diseases. Researchers will be able to see data such as age and gender, but they will not see names, dates of birth, or contact information.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 day
Maximum Age: 120
Healthy Volunteers: f
View:

⁃ In order to be eligible to participate in this study, an individual must meet all of the following criteria:

⁃ The participant must present with characteristics consistent with one of the following diagnoses:

• Aniridia

• Best disease

• Blue-cone monochromacy

• Corneal dystrophy

• Other hypopigmentation disorder affecting vision (e.g., Oculocutaneous and ocular albinism, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome)

⁃ OR

⁃ The participant must be a direct, close relative of an affected participant.

⁃ OR

⁃ A participant who also participated in the eyeGENE Stage 1 protocol who may benefit from further genetic testing.

Locations
United States
Maryland
National Eye Institute (NEI)
RECRUITING
Bethesda
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
eyeGene Coordinating Center
neieyegeneinfo@nih.gov
(301) 435-3032
Backup
Brian P Brooks, M.D.
brooksb@mail.nih.gov
(301) 451-2238
Time Frame
Start Date: 2024-07-12
Estimated Completion Date: 2054-06-27
Participants
Target number of participants: 1000
Treatments
Participants
Participants with inherited eye diseases or relative of affected participant
Related Therapeutic Areas
Hypomelanotic Disorder
Aniridia
Adult-Onset Vitelliform Macular Dystrophy (AVMD)
Albinism
Late-Onset Retinal Degeneration
Age-Related Macular Degeneration (ARMD)
Sponsors
Leads: National Eye Institute (NEI)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

An Observational Prospective Natural History Study of Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

An Observational Prospective Natural History Study of Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

Enrollment Status: Recruiting
Publish Date: October 02, 2025

NEI Intramural Biorepository for Retinal Diseases

NEI Intramural Biorepository for Retinal Diseases

Enrollment Status: Recruiting
Publish Date: October 14, 2025

A Phase I/IIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

A Phase I/IIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

Who is this study for: Patients with Age-Related Macular Degeneration
Enrollment Status: Recruiting
Publish Date: September 24, 2025
Intervention Type: Drug
Study Drug: iPSC-Derived Retinal Pigment Epithelium/Poly Lactic-Co-Glycolic Acid Transplantation
Study Phase: Phase 1/Phase 2
View All
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved